Healthy Skepticism Library item: 891

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Apuzzo M.
Drugs to Quit Smoking Said Show Promise
Associated Press 2005 Mar 8

Full text:

Researchers are racing to develop a potentially lucrative drug that would
make smoking as treatable as erectile disfunction, high cholesterol and acid
reflux disease.

Major pharmaceutical companies and small startups see the potential for
billions of dollars in sales for a vaccine or a nicotine-free pill that
could end addiction at the chemical level for America’s 50 million smokers.

“It’s the biggest addiction market there is,” said Dr. Herbert D. Kleber, a
psychiatry professor and addiction researcher at Columbia University. “Is it
realistic to be able to help addicts stop smoking and remain off with a
pill? I think the answer is yes and we’re working on a number of them.”

While nicotine patches, gums, lozenges and sprays help wean smokers off
cigarettes by slowly reducing their dependence on nicotine, researchers are
tailoring drugs to mimic or block nicotine’s chemical reactions with the
body.

In Connecticut, researchers at Pfizer Inc. identified a brain receptor that
nicotine binds to and designed a drug, varenicline, that latches to the same
site. Varenicline is in Phase III testing, normally the last step before a
company applies for approval from the Food and Drug Administration.

Researchers hope that the drug will attach to nicotine receptors in the
brain, preventing overpowering cravings from setting in when someone stops
smoking.

If varenicline’s claims hold up, the drug could generate more than $500
million a year in sales, said David Moskowitz, an analyst with Friedman,
Billings, Ramsey & Co.

“It’s an unmet medical need,” said Dr. Karen Reeves, executive director of
clinical development for Pfizer. “The morbidity and mortality rate is so
high, and doctors and smokers really have not had enough in their
armamentarium to help smokers stop smoking.”

The French pharmaceutical company Sanofi-Synthelabo said it will ask for FDA
approval this year for the drug rimonabant, which it would market under the
name Acomplia as a way to help stop smoking and overeating.

Acomplia targets circuitry in the brain that encourages smokers to keep
lighting up. If the body’s chemical reward system is blocked, smoking might
not be as pleasurable or as addictive.

Researchers have high hopes for the drug, saying it might also treat alcohol
and drug abuse.

That combination could translate into billions in yearly sales, Moskowitz
said.

Then there’s NicVax, a drug that Florida-based Nabi Pharmaceuticals claims
could be used as a nicotine vaccine. NicVax triggers the production of
antibodies that bind to nicotine molecules, preventing them from reacting
with receptors in the brain.

NicVax, which was developed primarily with grants from the National
Institute on Drug Abuse, has shown promise in early trials and could begin
Phase III testing late this year, the company said.

A similar drug, called Ta-Nic, is in early testing by the Xenova Group in
England.

“Everyone has been looking for the magic bullet,” said Thomas Glynn,
director of cancer science and trends for the American Cancer Society.

Whether one will be found remains uncertain, he said. It’s more likely,
doctors agree, that scientists will develop a number of successful drugs
that will prove effective, but no single pill will “cure” smoking.

Doctors with high hopes have been let down before. In 1997, the FDA approved
bupropion, commonly sold under the name Zyban, as an anti-smoking drug.

The drug, which was originally marketed as an antidepressant, has proven
successful for some smokers but was never the industry blockbuster some
expected.

Dr. Cheryl Oncken, associate professor of medicine at the University of
Connecticut Health Center, said the new drugs being developed represent the
next generation of medicine. Oncken will present a research study this
weekend on varenicline, which in an earlier Pfizer study was shown to help
nearly half of smokers quit within seven weeks < compared to about 33
percent with bupropion.

Investors are proceeding cautiously. Scott Henry, a Pfizer analyst at
Oppenheimer & Co., said it’s too early to tell whether there is a smoking
wonder drug in development. He said varenicline has shown promise, but like
all drugs being tested, there are many unanswered questions.

“Is it truly a revolutionary new treatment, or is just another bell and
whistle?” he said.